Edition:
United States

Intercept Pharmaceuticals Inc (ICPT.OQ)

ICPT.OQ on NASDAQ Stock Exchange Global Select Market

132.29USD
23 Jun 2017
Change (% chg)

$1.72 (+1.32%)
Prev Close
$130.57
Open
$130.34
Day's High
$132.43
Day's Low
$127.19
Volume
158,817
Avg. Vol
138,297
52-wk High
$177.74
52-wk Low
$96.76

ICPT.OQ

Chart for ICPT.OQ

About

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic... (more)

Overall

Beta: -1.95
Market Cap(Mil.): $3,308.46
Shares Outstanding(Mil.): 25.01
Dividend: --
Yield (%): --

Financials

  ICPT.OQ Industry Sector
P/E (TTM): -- 239.63 19.01
EPS (TTM): -15.18 -- --
ROI: -69.04 -8.17 -5.03
ROE: -103.24 -11.48 -4.28

BRIEF-Intercept announces new data analysis from FLINT trial of OCA

* Intercept announces new data analysis from FLINT trial of OCA in nash patients with type 2 diabetes

Jun 12 2017

BRIEF-Health Canada grants approval for Ocaliva

* Health Canada grants approval for Ocaliva (obeticholic acid) for the treatment of patients with primary biliary cholangitis (pbc)

May 25 2017

BRIEF-Intercept Pharmaceuticals files for potential mixed shelf offering

* Files for potential mixed shelf offering; size not disclosed - SEC filing Source text: (http://bit.ly/2r1bYv5) Further company coverage:

May 10 2017

BRIEF-Intercept Pharmaceuticals reports Q4 sales $13.8 mln

* Intercept pharmaceuticals reports full year 2016 financial results and provides business update

Feb 23 2017

BRIEF-Intercept Pharmaceuticals to update on trial of liver fibrosis treatment

* Intercept to provide update on phase 3 regenerate trial of obeticholic acid for the treatment of nash patients with liver fibrosis Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Feb 10 2017

More From Around the Web

Earnings vs. Estimates